SCHEMBL1396815

SCHEMBL1396815

CN(C[C@H]1CCCN1OC(=O)OC(C)(C)C)c1cccc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.40
▸ ACHE P22303 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.35
▸ CHRM3 P20309 8/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ OPRL1 P41146 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ STAT6 P42226 1/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2545927 0.84 RIPK1 (0.46) RIPK1GPR119HTR2AHTR2C
SCHEMBL16105192 0.76 RIPK1 (0.43) RIPK1ACHEFFAR1
SCHEMBL1396904 0.74 HTR7 (0.44) CHRM3
SCHEMBL1396828 0.70 POLB (0.42) MAPT
SCHEMBL3956320 0.69 HTT (0.35) MAPT
SCHEMBL3952875 0.69 HTT (0.35) MAPT
SCHEMBL4764196 0.68 RIPK1 (0.49) RIPK1GPR119MAPT
SCHEMBL4764197 0.68 RIPK1 (0.49) RIPK1GPR119MAPT
SCHEMBL1526816 0.67 POLB (0.38) —
SCHEMBL331034 0.66 USP30 (0.53) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288351-B1 NOVEL PYRROLIDONE DERIVATIVES FOR USE AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2018-08-08 — — EP disclosed
EP-2288351-A2 NOVEL PYRROLIDONE DERIVATIVES FOR USE AS METAP-2 INHIBITORS Merck Patent GmbH (DE) 2011-03-02 — — EP disclosed
WO-2010003475-A2 NOVEL PYRROLIDONE DERIVATIVES FOR USE AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2010-01-14 — — WO disclosed
Send feedback